Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy

An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity. A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cancer vaccines and lack of a safe and efficient adjuvant for human use. We discovered...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aihua Wu, Yingzhi Chen, Hairui Wang, Ya Chang, Meng Zhang, Pengfei Zhao, Yisi Tang, Qin Xu, Zhuangzhi Zhu, Yang Cao, Yongzhuo Huang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Trichosanthin Legumain TRP2 Transcutaneous immunization Adjuvant Cancer vaccine Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/eda5c3f270624e1ebbeea6bba12704d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eda5c3f270624e1ebbeea6bba12704d1
record_format	dspace
spelling	oai:doaj.org-article:eda5c3f270624e1ebbeea6bba12704d12021-12-02T05:01:25ZGenetically-engineered “all-in-one” vaccine platform for cancer immunotherapy2211-383510.1016/j.apsb.2021.06.001https://doaj.org/article/eda5c3f270624e1ebbeea6bba12704d12021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2211383521002136https://doaj.org/toc/2211-3835An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity. A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cancer vaccines and lack of a safe and efficient adjuvant for human use. We discovered a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide, TCS, and a cell-penetrating peptide (CPP), termed an “all-in-one” vaccine, for transcutaneous cancer immunization. The TCS adjuvant effect on antigen presentation was investigated and the antitumor immunity of the vaccines was investigated using the different tumor models. The vaccines were prepared via a facile recombinant method. The vaccines induced the maturation of DCs that subsequently primed CD8+ T cells. The TCS-based immunostimulation was associated with the STING pathway. The general applicability of this genetic engineering strategy was demonstrated with various tumor antigens (i.e., legumain and TRP2 antigenic peptides) and tumor models (i.e., colon tumor and melanoma). These findings represent a useful protocol for developing cancer vaccines at low cost and time-saving, and demonstrates the adjuvant application of TCS—an old drug for a new application.Aihua WuYingzhi ChenHairui WangYa ChangMeng ZhangPengfei ZhaoYisi TangQin XuZhuangzhi ZhuYang CaoYongzhuo HuangElsevierarticleTrichosanthinLegumainTRP2Transcutaneous immunizationAdjuvantCancer vaccineTherapeutics. PharmacologyRM1-950ENActa Pharmaceutica Sinica B, Vol 11, Iss 11, Pp 3622-3635 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Trichosanthin Legumain TRP2 Transcutaneous immunization Adjuvant Cancer vaccine Therapeutics. Pharmacology RM1-950
spellingShingle	Trichosanthin Legumain TRP2 Transcutaneous immunization Adjuvant Cancer vaccine Therapeutics. Pharmacology RM1-950 Aihua Wu Yingzhi Chen Hairui Wang Ya Chang Meng Zhang Pengfei Zhao Yisi Tang Qin Xu Zhuangzhi Zhu Yang Cao Yongzhuo Huang Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
description	An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity. A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cancer vaccines and lack of a safe and efficient adjuvant for human use. We discovered a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide, TCS, and a cell-penetrating peptide (CPP), termed an “all-in-one” vaccine, for transcutaneous cancer immunization. The TCS adjuvant effect on antigen presentation was investigated and the antitumor immunity of the vaccines was investigated using the different tumor models. The vaccines were prepared via a facile recombinant method. The vaccines induced the maturation of DCs that subsequently primed CD8+ T cells. The TCS-based immunostimulation was associated with the STING pathway. The general applicability of this genetic engineering strategy was demonstrated with various tumor antigens (i.e., legumain and TRP2 antigenic peptides) and tumor models (i.e., colon tumor and melanoma). These findings represent a useful protocol for developing cancer vaccines at low cost and time-saving, and demonstrates the adjuvant application of TCS—an old drug for a new application.
format	article
author	Aihua Wu Yingzhi Chen Hairui Wang Ya Chang Meng Zhang Pengfei Zhao Yisi Tang Qin Xu Zhuangzhi Zhu Yang Cao Yongzhuo Huang
author_facet	Aihua Wu Yingzhi Chen Hairui Wang Ya Chang Meng Zhang Pengfei Zhao Yisi Tang Qin Xu Zhuangzhi Zhu Yang Cao Yongzhuo Huang
author_sort	Aihua Wu
title	Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
title_short	Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
title_full	Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
title_fullStr	Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
title_full_unstemmed	Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
title_sort	genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/eda5c3f270624e1ebbeea6bba12704d1
work_keys_str_mv	AT aihuawu geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT yingzhichen geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT hairuiwang geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT yachang geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT mengzhang geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT pengfeizhao geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT yisitang geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT qinxu geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT zhuangzhizhu geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT yangcao geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy AT yongzhuohuang geneticallyengineeredallinonevaccineplatformforcancerimmunotherapy
_version_	1718400865048461312

Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy

Ejemplares similares